Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.

Disclosed herein are spherical high-density lipoprotein-like nanoparticles (HDL-NP) having a soft material core (e.g., a lipid-conjugated inorganic core). Also disclosed herein are methods for synthesizing the spherical HDL-NPs. Also disclosed herein are methods for treating disorders such as cardiovascular disease, cancer, inflammatory disorders or reducing NF-kB activity with the spherical HDL-NPs.

The present invention relates to a stable, solid composition of Azilsartan or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient(s); optionally, the said composition further comprises a diuretic, preferably a thiazide diuretic such as Chlorthalidone, and processes for its preparation.

The present disclosure relates to a polypeptide exhibiting granulocyte-colony stimulating factor activity. The polypeptide comprises at least one non-native cysteine residue at a site selected from the group consisting of T.sub.1CP.sub.2 (SEQ ID NO: 25), P.sub.2CL.sub.3 (SEQ ID NO: 26), L.sub.3CG.sub.4 (SEQ ID NO: 27), G.sub.4CP.sub.5 (SEQ ID NO: 28), P.sub.5CA.sub.6 (SEQ ID NO: 29), A.sub.6CS.sub.7 (SEQ ID NO: 30), S.sub.96CP.sub.97 (SEQ ID NO: 31), P.sub.97CE.sub.98 (SEQ ID NO: 32), L.sub.99CG.sub.100 (SEQ ID NO: 33), P.sub.101CT.sub.102 (SEQ ID NO: 34), E.sub.122CE.sub.123 (SEQ ID NO: 35), L.sub.124CG.sub.125 (SEQ ID NO: 36), M.sub.126CA.sub.127 (SEQ ID NO: 37), P.sub.138CA.sub.139 (SEQ ID NO: 39), A.sub.143CF.sub.144 (SEQ ID NO: 40), R.sub.146CR.sub.147 (SEQ ID NO: 41), R.sub.169CH.sub.170 (SEQ ID NO: 42), H.sub.170CL.sub.171 (SEQ ID NO: 43), L.sub.171CA.sub.172 (SEQ ID NO: 44), A.sub.172CQ.sub.173 (SEQ ID NO: 45), and Q.sub.173CP.sub.174 (SEQ ID NO: 46) in an amino acid sequence having at least 90% sequence identity to sequence set forth in SEQ ID NO: 2.

The present invention relates to the use of surface-reacted calcium carbonate as stabilizing agent for a probiotic composition, wherein the surface-reacted calcium carbonate is a reaction product of natural ground calcium carbonate or precipitated calcium carbonate with carbon dioxide and one or more H.sub.3O.sup.+ ion donors, wherein the carbon dioxide is formed in situ by the H.sub.3O.sup.+ ion donors treatment and/or is supplied from an external source.

Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

An improved agent and treatment method for a broad variety of diseases in both animals and humans are disclosed. The agent is an inventive treatment compound comprising a bacterial-based culture. The inventive treatment compound has a positive impact on the gut health of boilers from the earliest stage onward. These benefits are realized through several mechanisms, including improved gut morphology under disease stress. Healthier gut morphology and improved gut integrity result in improved nutrient uptake and growth benefits, both based on consumption of the disclosed inventive treatment compound. The downstream results are improvements in performance parameters related to gut health including altering gut microbes, feed conversion rates, and body weight gains among others. Use of the disclosed treatment compound has the further benefit of avoiding contamination during animal processing because of the reduction in the volume of pathogenic bacteria in the gut.

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

The present disclosure provides a crystalline form of the methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compound of the structure: XRPD, TGA, and DSC data on the crystalline form, as well as methods preparing the crystalline form, including a multi-kilo scale preparation. Also provided are pharmaceutical compositions and methods of treating p38 mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis. and methods of maximizing the yield thereof comprising administering of the compound. Also provided is a method of maximizing the yield of said compound via a recycling procedure.

A method of preventing progression of an appearance or effect of aging in a subject is provided. A method of preventing, limiting, or inhibiting injury to skin integrity in a subject is also provided. A method of substantially maintaining a state of skin integrity in a subject is further provided. A method of preventing a topographical change of a cutaneous layer of skin in a subject is still further provided. The methods comprise administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject. Related preparations and kits are also provided.